Diabeloop and Sequel Med Tech Partner to Bring Closed-Loop Insulin Delivery to the US

Diabeloop and Sequel Med Tech have announced a strategic collaboration following FDA 510(k) clearance for DBLG2 on December 18, 2025.

The agreement integrates Diabeloop’s DBLG2 algorithm into Sequel’s twiist Automated Insulin Delivery (AID) system. The integrated system will launch in the US market first, with potential international expansion later.

What the FDA Clearance Enables?

DBLG2 was cleared as an Interoperable Automated Glycaemic Controller (iAGC).

This clearance allows:

• Integration with compatible insulin pumps
• Greater flexibility across AID ecosystems
• Faster innovation through modular AID components

The partnership moves twiist closer to a fully closed-loop insulin delivery system.

Why This Integration Matters?

This marks the first commercial integration of the Diabeloop algorithm in a US insulin pump. The collaboration focuses on three priorities:

• Proven clinical outcomes
• Ease of use
• Deep personalization for people with type 1 diabetes

Diabeloop continues its strategy of partnering with pump manufacturers to expand user choice.

Executive Perspective

François Miceli, CEO of Diabeloop, called the partnership a major milestone. He emphasized:

• First US access to Diabeloop technology
• Simplified diabetes management
• No compromise on clinical performance

This becomes Diabeloop’s fifth official pump integration, after Roche, ViCentra, Terumo, and Sooil.

twiist’s Differentiated Approach

According to Sequel Med Tech’s Alan Lotvin, diabetes technology must adapt to individuals. The twiist AID system stands out by offering:

• Multiple algorithm options
• User-driven personalization
• Flexibility across different diabetes needs

twiist aims to give users more freedom without sacrificing glucose control.

How the DBLG2 Algorithm Works?

DBLG2 is designed to reduce the mental burden of diabetes management. Key features include:

• Real-time analysis of CGM data
• Automatic insulin adjustments
• Focus on keeping glucose within target range

Initialization is intentionally simple.

Users enter only:

• Body weight
• Total daily insulin dose

From there, the system learns continuously.

Self-Learning and Personalization

DBLG2 includes a self-learning module. Over time, it adapts based on:

• Glucose trends
• Insulin delivery history
• Individual physiology and preferences

This allows the algorithm to respond to diverse Type 1 diabetes profiles.

Moving Toward Full Closed-Loop Control

DBLG2 supports optional meal declaration.

• Users may skip meal announcements
• The system continues automated glucose management
• Best control is achieved when meals are declared

This flexibility pushes the system closer to true closed-loop operation.

About the twiist AID System

The twiist AID System introduces a unique technical capability. It is the first insulin delivery system to:

• Directly measure insulin volume per micro-dose

Additional highlights:

• Cleared for ages six and up
• Adapts dosing to individual needs
• Uses the community-driven Tidepool Loop–based algorithm

Basal insulin is adjusted automatically using predicted glucose levels.

Company Snapshots

Diabeloop: Founded in 2015, Diabeloop develops AI-driven diabetes automation solutions.
Its algorithms connect CGMs and pumps to reduce daily treatment decisions.

Sequel Med Tech: Headquartered in Manchester, New Hampshire.
Focused on next-generation drug delivery systems that simplify disease management.

Bottom Line

This collaboration brings Diabeloop’s adaptive algorithm to the US pump market for the first time. For people with type 1 diabetes, it signals:

• More choice
• Greater personalization
• A step closer to fully automated insulin delivery

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!